Specific and Nonspecific Immunoprophilaxis of Respiratory Infections and Flu in Children with Allergic Diseases

Relevance. The only way to reduce the incidence of vaccination-controlled infections and to prevent epidemics at the current stage is a 95% preventive vaccination coverage. It means that not only healthy children are subject to vaccination, but also children with various diseases.

Object: to justify the need of specific and nonspecific immunoprophilaxis of respiratory infections and flu for children with allergic diseases.

Patients and methods. Comparative analysis of domestic and foreign-made polymer subunit vaccine tolerance was conducted among 335 children aged 3–17 years with various allergic diseases. The research was conducted during three seasons of epidemics — 2011–2014 years. The subjects of analysis were vaccination tolerance, course of the underlying disease and the frequency of acute respiratory infections within one year after immunization. Specific immune response was assessed 1 and 6 months after vaccination.

Results. The lower quantity and severity of weak local and general reactions was observed in all groups of children (both healthy and with allergic diseases) immunized by the domestic vaccine. No significant differences in immunogenicity of domestic and foreign-made influenza vaccines were detected. Furthermore, the level of postvaccination immunity remains high after immunization of patients with both bronchial asthma and atopic dermatitis. No cases of exacerbation of chronic disease associated with influenza vaccination are detected. Reduction of bronchial asthma frequency was associated with a reduction of acute respiratory infections frequency.

Conclusion. Vaccination of healthy children and children with bronchial asthma and atopic dermatitis is an essential and secure measure that increases the efficiency of patients with current treatment of various allergic diseases and decreases the frequency of flu and acute respiratory infections.

1. Намазова-Баранова Л. С., Торшхоева Р. М., Ботвиньева В. В., Таги-заде Т. Г., Таранушенко Т. Е. Часто болеющие дети мегаполисов: лечение и профилактика острых респираторных инфекций. Педиатрическая фармакология. 2006; 3 (1): 13–17.

2. Баранов А. А., Балаболкин И. И. Детская аллергология. Москва: ГЭОТАР-Медиа. 2006. 688 с.

3. Gustafsson D., Sjoberg O., Foucard T. et al. Development of allergies and asthma in infants and young children with atopic dermatitis: a prospective tollow-up to 7 years of age. Allergy. 2000; 55: 240–245.

4. Баранов А. А., Хаитов Р. М. Аллергология и иммунология. Клинические рекомендации для педиатров. Москва: Союз педиатров России. 2011. С. 33.

5. Костинов М. П., Гурвич Э. Б. Вакцины нового поколения в профилактике инфекционных заболеваний. М.: Медицина для всех. 2002. 152 с.

6. URL: Http://www.who.int/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_2005_4/en/

7. Чувиров Д. Г., Ярцев М. Н. Изучение переносимости и клинической эффективности препарата Полиоксидоний у детей с повторными инфекциями дыхательных путей. Материалы 4-го Конгресса «Со вре менные проблемы аллергологии, клинической иммунологии и иммуно фармакологии», 29–31 мая 2001 г. Москва: ВИНИТИ. 2001. С. 307.

8. URL: http://pharmso.ru/news-2901.html

9. URL: http://www.who.int/csr/disease/avian_influenza/phase/en/index.html

10. ВОЗ. Рекомендации по использованию инактивированных противогриппозных вакцин и других профилактических мер. Weekly Epidemiological Record. 2012; 75: 281–288.

11. Europian Scientific Working group on Influenzae. URL: http://www.eswi.org/influenzae-facts/introduction

12. Зверев В. В., Хаитов Р. М. Вакцины и вакцинация. Националь ное руководство. Москва. 2014. С. 110.

13. Караулов А. В. Полиоксидоний в клинической практике. Москва: ГЭОТАР-Медиа. 2008. С. 136.